Sponsor Overview
Explore verified public information about Ariad Pharmaceuticals's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 1 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 2 supporting sources.
Conditions: Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma
Conditions: Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.